A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Jara, Michele ^a   Wentworth III, Charles ^b   Lanes, Stephan ^b  

^a ACORDA THERAPEUTICS INC   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FORMOTEROL; HANDIHALER; IPRATROPIUM BROMIDE; LONG ACTING DRUG; RESPIMAT; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEURYSM; ANGINA PECTORIS; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DISEASE EXACERBATION; DRUG FATALITY; DRUG SAFETY; DYSPHAGIA; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTITIONER; HAZARD RATIO; HEALTH CARE SYSTEM; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PNEUMONIA; PROPENSITY SCORE; STROKE; SYNCOPE; TACHYCARDIA; TREMOR; UNITED KINGDOM; URINE RETENTION; XEROSTOMIA;

EID: 84863657697     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000841     Document Type: Article

References (43)

1. Peters NL. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Int Med 1989;149:2414-20. (Pubitemid 19283196)
2. Boehringer Ingelheim International. Summary of Product Characteristics. Spiriva 18 Microgram Inhalation Powder, Hard Capsule. Bracknell, Berkshire, UK: Boehringer Ingelheim, 2010. http://www.medicines.org.uk/emc/medicine/ 10039#UNDESIRABLE-EFFECTS (accessed 16 Jan 2010).
3. Boehringer Ingelheim International. Summary of Product Characteristics. Atrovent Inhaler CFC-Free. Bracknell, Berkshire, UK: Boehringer Ingelheim, 2010. http://www.medicines.org.uk/emc/medicine/14332/SPC/#UNDESIRABLE-EFFECTS (accessed 16 Jan 2010).
4. Mintzer J, Burns A. Anticholinergic side effects of drugs in elderly people. J R Soc Med 2000;93:457-62.
5. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3:335-48.
6. Parlow JL, van Vlyman JM, Odell MJ. The duration of impairment of autonomic control after anticholinergic drug administration in humans. Anesth Analg 1997;84:155-9. (Pubitemid 27020976)
7. Mathew J, Hunsberger S, Fleg J, et al. Incidence, prognostic factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-22.
8. Glotzer TV, Hellkamp AS, Zimmerman J, et al; the MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke Circulation 2003;107:1614-19.
9. Pauwels R, Buist A, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76. (Pubitemid 32378468)
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
11. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858-68.
12. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7. (Pubitemid 39534583)
13. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care Thorax 2010;65:956-62.
14. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. (Pubitemid 46656860)
15. Rothman KJ, Greenland S. Modern Epidemiology. 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1998.
16. Rosenbaum PR, Rubin DP. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
17. Rubin DB. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 2005;13:855-7.
18. Anthonisen NR, Connett JE, Enright PL, et al; The lung health study research group. Hospitalizations mortality lung health study. Am J Resp Crit Care Med 2002;166:333-9. (Pubitemid 34864422)
19. Macie C, Wooldrage K, Manfreda J, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. J Chron Obstruct Pulmon Dis 2008;3:163-9. (Pubitemid 351523729)
20. Ogale S, Lee T, Au D, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137:13-19.
21. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90.
22. Food and Drug Administration. Early Communication About An Ongoing Safety Review Of Tiotropium (Marketed as Spiriva HandiHaler). Silver Spring, MD: Food and Drug Administration, 2008. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070651.htm (accessed 10 Jun 2009).
23. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1534-54.
24. ClinicalTrials.gov. US National Institutes of Health. Evaluation of the Long-Term Effects Of Spiriva On Lung Function in COPD Patients. NCT00144339 NCT00144339: NIH, 2005. http://clinicaltrials.gov/ct2/show/results/NCT00144339 (accessed 10 Jun 2009).
25. Boehringer Ingelheim International. Briefing Document: Tiotropium (SPIRIVA®): Pulmonary Allergy Drug Advisory Meeting - November 2009. Briefing Information for the November 19, 2009. Meeting of the Pulmonary-Allergy Drugs Advisory Committee, 2009:115. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary- AllergyDrugsAdvisoryCommittee/UCM190466.pdf (accessed 10 Jun 2009).
26. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee Meeting. November 19. FDA Briefing Material. Briefing Information for the November 19, 2009 Meeting of the Pulmonary-Allergy Drugs Advisory Committee. FDA, 2009:115. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ UCM190752.pdf (accessed 10 Jun 2009).
27. Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Resp Med 2010;105:571-9.
28. Wedzicha JA, Calverly PMA, Seemungal TA, et al. Inspire Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
29. Gershon ACR, To T, Stanbrook MB, et al. Comparison of inhaled long-acting beta-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease. Ann Intern Med 2011;154:583-92.
30. Celli B DM, Leimer I, Vogel U, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.
31. Kesten SCB, Decramer M, Leimer I, et al. Tiotropium handihaler in the treatment of COPD: a safety review. Int J COPD 2009;4:397-409.
32. Kesten SJM, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703. (Pubitemid 46033421)
33. Vogelmeier C, Hederer B, Glabb T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
34. US National Institutes of Health. Effect of Inhalation Of Tiotropium Once Daily 18 mcg Versus Salmeterol Twice Daily 50 mcg On Time To First Exacerbation in COPD Patients (A Randomised, Double-Blind, Double-Dummy, Parallel Group, One-Year Study). NCT00563381. NCT, 2011. http://clinicaltrials.gov/ct2/results? term=nct00563381 (accessed 19 Apr 2012).
35. Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.
36. Cates CJ. Safety of tiotropium. BMJ 2011;342:d2970.
37. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium respimat SMI in COPD in two 1-year randomized studies. Int J COPD 2010;5:197-208.
38. Boehringer Ingelheim International. A Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess Long Term (One-Year) Efficacy And Safety Of Tiotropium Inhalation Solution 5 mcg (2 Puffs of 2.5 mcg) Delivered By The Respimat Inhaler In Patients With Chronic Obstructive Pulmonary Disease Boehringer Ingelheim Trial Results. 2009. http://trials.boehringer- ingelheim.com/res/trial/data/pdf/205.372-U09-1128-01.pdf (accessed 10 Jun 2009).
39. Bateman EDTD, Siafakas N, Dahl R, et al. A one-year trial of tiotropium respimat plus usual therapy in COPD pateints. Resp Med 2010;104:1460-72.
40. Boehringer Ingelheim International. Summary of Product Characteristics, Spiriva Respimat 2.5 Micrograms Solution For Inhalation. 2010. http://www.medicines.org.uk/EMC/medicine/20134/SPC/Spiriva+Respimat+2. 5+micrograms+solution+for+inhalation/ (accessed 16 Jan 2010).
41. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.
42. Rothman KJ. Significance questing. Ann Int Med 1986;105:445-7. (Pubitemid 16014317)
43. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee Meeting. FDA Main Presentations for the February 23, 2012 Meeting of the pulmonary-Allergy drugs Advisory Committee. 2012. Slide 60/109. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM293997.pdf (accessed 23 Apr 2012).